MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
ROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
Express News | MaxCyte Signs License Agreement With Legend Biotech, Under Which Legend Obtains Non-Exclusive Worldwide License To Use MaxCyte's Flow Electroporation And ExPERT Platform; MaxCyte Eligible For Fees And Miletones
Express News | MaxCyte Inc - Upon Successful Commercialization, Is Eligible to Receive Licensing Fees and Royalties on Net Sales of Licensed Products
Express News | MaxCyte Inc - Will Be Eligible to Receive Annual Licensing Fees and Milestones From Legend Biotech During Clinical Development
Express News | MaxCyte Inc - Under Terms, Legend Biotech Obtains a Non-Exclusive Worldwide License to Use Co's Flow Electroporation Technology and Expert Platform
Express News | MaxCyte, Inc. MaxCyte, Inc. - Mxcr - Signing of Strategic Platform License
Express News | MaxCyte Signs Strategic Platform License Agreement With Legend Biotech to Accelerate Cell Therapy Discovery and Development
BlackRock Increases Stake in MaxCyte, Inc.
BlackRock Acquires Major Stake in MaxCyte
Vicore Expands and Strengthens Its Board of Directors
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript
Earnings Call Summary | MaxCyte(MXCT.US) Q1 2024 Earnings Conference
The following is a summary of the MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript:Financial Performance:MaxCyte reported a total revenue of $11.3 million in Q1 2024, a rise of 32% from the $8.6
MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript
MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript
MaxCyte Shares Rise Sharply After Q1 Results Beat
MaxCyte (MXCT) shares were up more than 20% in recent Wednesday trading after the company reported better-than-expected Q1 results in the previous day. The company reported late Tuesday a Q1 loss of $
MaxCyte Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
MaxCyte Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Express News | MaxCyte Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results
ISUN, DTCK and MXCT Among Mid-day Movers
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersMaxCyte (NASDAQ:MXCT) shares rose 26.5% to $4.97 during Wednesday's regular session. The company's market cap stands at $519.4 million. The company's, Q1 earnings came out yesterday. Elanco Ani
MaxCyte Up Over 27%, on Track for Record Percent Increase -- Data Talk
MaxCyte, Inc. (MXCT) is currently at $5.00, up $1.07 or 27.23% --Would be highest close since Feb. 2, 2024, when it closed at $5.15 --Would be largest percent increase on record (Based on available
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones gaining around 70 points on Wednesday.Shares of Louisiana-Pacific Corporation (NYSE:LPX) rose sharply during Wednesday's session following better-than-expec
No Data